Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings implicate the involvement of both androgens and the AR in bladder cancer.
|
17406000 |
2007 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CAG repeats in the androgen receptor gene are shorter in patients with pulmonary, esophageal or bladder carcinoma and longer in women with uterine leiomyoma.
|
20127024 |
2010 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer.
|
22218302 |
2012 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of androgen receptor in cell growth and drug sensitivity was also evaluated in vitro and in vivo in several bladder cancer cell lines.
|
22608749 |
2012 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, crosstalk between AR and EGFR pathways in bladder cancer remains uncharacterized.
|
22922989 |
2012 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Determination of the AR status in cystectomy specimens offers new therapeutic approaches in locally advanced bladder cancer.
|
23330817 |
2013 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
We then assessed the effects of androgen on β-catenin in AR-positive and AR-negative bladder cancer cell lines.
|
23447569 |
2013 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our results indicate that EGF may be able to potentiate AR transactivation that leads to enhancing BCa progression, which may help us to develop a better therapeutic approach to treat BCa via targeting both EGF and AR signaling.
|
24126741 |
2013 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It is concluded that suppression of AR expression decreased the production of TGF-β, inhibiting EMT and bladder cancer cell growth in vitro and in vivo, implying that its use might be a potential therapeutic target for the treatment of bladder cancer.
|
24329492 |
2014 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition.
|
24662746 |
2014 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We discuss work demonstrating AR expression in bladder cancer and its role in promoting formation and progression of tumors.
|
26229034 |
2015 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies suggest that the androgen receptor (AR) might play important roles in influencing bladder cancer progression, yet its clinical application remains unclear.
|
26264279 |
2015 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Importantly, ELK1 appears to require activated AR to regulate bladder cancer cell proliferation, but not cell migration.
|
26342199 |
2015 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Conditional Expression of the Androgen Receptor Increases Susceptibility of Bladder Cancer in Mice.
|
26862755 |
2016 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, in vivo mouse models of xenografted bladder cancer T24 cells with CD4(+) T cells confirmed in vitro coculture studies and concluded that infiltrating CD4(+) T cells can promote bladder cancer metastasis via modulation of the IL1→AR→HIF1α→VEGFa signaling.
|
27196763 |
2016 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thiazolyl blue cell viability assay, flow cytometry, scratch wound-healing assay, transwell invasion assay, real-time polymerase chain reaction, and reporter gene assay were performed in AR-positive (e.g., UMUC3, TCCSUP, and 647V-AR) and AR-negative (e.g., UMUC3-AR-short hairpin RNA [shRNA], TCCSUP-AR-shRNA, 647V) bladder cancer lines treated with dihydrotestosterone and each AR antagonist.
|
27330033 |
2016 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that enzalutamide may have the potential to treat patients with advanced gemcitabine-resistant bladder cancer with increased AR expression.
|
27909718 |
2017 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Areas covered: We summarize and discuss available data suggesting the involvement of AR and its potential downstream targets in the development and progression of bladder cancer.
|
28064545 |
2017 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, androgen-mediated androgen receptor signals have been shown to correlate with the promotion of tumor development and progression, which may clearly explain some sex-specific differences in bladder cancer.
|
28241422 |
2017 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given that the androgen receptor (AR) has been discussed as a possible factor in the development and progression of bladder cancer, we investigated the predictive value of AR in stage pT1 NMIBC.
|
28342317 |
2017 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We therefore conducted this meta-analysis to assess the clinicopathological impact of the expression of androgen receptor (AR) and estrogen receptors (ERs) in bladder cancer.
|
28362839 |
2017 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The correlations of miR-124 with XIST and AR in bladder cancer samples were statistically analyzed.
|
28869948 |
2017 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emerging preclinical evidence suggests the critical role of androgen-mediated androgen receptor (AR) signals in the development of bladder cancer.
|
29119053 |
2017 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
NF-κB activators and inhibitors also significantly induced and reduced, respectively, cell proliferation/migration/invasion of AR-positive bladder cancer lines, but not AR-knockdown or AR-negative lines, and their growth in xenograft-bearing mice.
|
29592878 |
2018 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen Receptor Is Inactivated and Degraded in Bladder Cancer Cells by Phenyl Glucosamine via miR-449a Restoration.
|
29659560 |
2018 |